Patents Examined by Lila Feisee
  • Patent number: 5948403
    Abstract: The present invention relates to a corneal angiogenesis inhibitor which has interferon .beta. as an active ingredient and which is used for preventing and treating neovascularization or invasion of vessels in the cornea.
    Type: Grant
    Filed: January 7, 1997
    Date of Patent: September 7, 1999
    Assignee: Toray Industries, Inc.
    Inventors: Saburo Sone, Akemi Kajita, Yu-ichiro Satoh
  • Patent number: 5948462
    Abstract: A method of preparing low fat sausage having a juicy feeling is provided by adding heat-denatured whey protein and emulsified composition comprising heat-denatured whey protein and edible oil and fat to raw material meat for sausage.The invention also provides low fat sausage which has the same meat structure and juicy feeling as usual sausage comprising animal fat such as hog fat and the like.
    Type: Grant
    Filed: March 25, 1997
    Date of Patent: September 7, 1999
    Assignee: Snow Brand Milk Products Co., Ltd.
    Inventors: Eiji Atsuta, Maki Maeda, Kaoru Sato, Masami Kawanari
  • Patent number: 5945308
    Abstract: The invention provides a human oxidized LDL receptor (HOLR) and polynucleotides which identify and encode HOLR. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HOLR.
    Type: Grant
    Filed: April 3, 1998
    Date of Patent: August 31, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Y. Tom Tang, Chandra Patterson, Neil C. Corley, Susan Sather
  • Patent number: 5945301
    Abstract: The invention relates to a kinase which is activated by transforming growth factor-.beta. (TGF-.beta.) and funstions in the TGF-.beta. family signal tranduction system. The invention further relates to a process of producing said kinase and to a gene encoding said kinase.
    Type: Grant
    Filed: July 24, 1996
    Date of Patent: August 31, 1999
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Naoto Ueno, Kunihiro Matsumoto, Kenji Irie
  • Patent number: 5942492
    Abstract: Cyclic peptide compounds having 11 amino acids joined by a linking unit L, such that the linear dimension between the C.sup..alpha. carbon of the first amino acid and the C.sup..alpha. carbon of eleventh amino acid is between about 4 and 12 .ANG.ngstrom units; are useful for inhibiting the binding of uPA to the uPAR receptor. Methods for using the cyclic peptide compounds, and compositions containing them, for inhibiting the growth or metastasis of cancerous tumors are also disclosed.
    Type: Grant
    Filed: November 12, 1996
    Date of Patent: August 24, 1999
    Assignee: Angstrom Pharmaceuticals, Inc.
    Inventors: Terence R. Jones, David N. Haney, Janos Varga
  • Patent number: 5939284
    Abstract: Human PPP1R5 polypeptides and DNA (RNA) encoding such PPP1R5 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such PPP1R5, or compounds which inhibit or stimulate PPP1R5 for dysfunctions or diseases which involve resistance to the action of insulin on glycogen synthesis are also disclosed. Agonist and antagonists of these PPP1R5 proteins and methods of their use are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the PPP1R5 and for detecting altered levels of the polypeptide in a host.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: August 17, 1999
    Assignee: Smithkline Beecham Corporation
    Inventors: Patricia T. W. Cohen, Phillip Cohen, Peter R. Young
  • Patent number: 5939531
    Abstract: The invention concerns recombinant antibodies directed to the extracellular domain of the human growth factor receptor c-erbB-2 comprising a light chain variable domain and a heavy chain variable domain of a monoclonal antibody, monoclonal antibodies directed to c-erbB-2 themselves, a method of manufacture of said recombinant antibodies and said monoclonal antibodies, hybridoma cells secreting said monoclonal antibodies, a method of manufacture of said hybridoma cells, DNA coding for the heavy chain variable domain, for the light chain variable domain and for the recombinant antibody, a method of manufacture of said DNA, hybrid vectors suitable for expression of said DNA, host cells transformed with said DNA, and the use of said recombinant antibodies and said monoclonal antibodies in the diagnosis and treatment of tumors.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: August 17, 1999
    Assignee: Novartis Corp.
    Inventors: Winfried Stephan Wels, Nancy E. Hynes, Ina-Maria Harwerth, Bernd Groner, Norman Hardman, Markus Zwickl
  • Patent number: 5939389
    Abstract: The use of C1-inactivator for the production of a pharmaceutical for the prophylaxis and treatment of capillary leak syndrome (generalized extravasation) and circulator shock (refractory hypotension) in severe burns or scalds, in polytrauma, in operations under conditions of extracorporeal circulation, in the use of cytokines, endogenous mediators, and mediator hybrids and growth factors produced by genetic engineering, or capillary leak syndrome and veno-occlusive disease of the liver in therapeutically or prophylactically indicated bone marrow transplantation is described.
    Type: Grant
    Filed: May 12, 1997
    Date of Patent: August 17, 1999
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Bernd Eisele, Ulrich Delvos, Andreas Jessel
  • Patent number: 5935796
    Abstract: This invention relates to methods and compositions for early diagnosis, monitoring and treatment of cartilage degenerative conditions, including forms of arthritis and are arthropathy, using an antibody which recognizes a peptide comprising the sequence FFGVG . . . generated by cleavage of cartilage aggrecan at the site N.sub.341 -F.sub.342.
    Type: Grant
    Filed: March 4, 1997
    Date of Patent: August 10, 1999
    Assignee: The University of Melbourne
    Inventor: Amanda Jane Fosang
  • Patent number: 5936064
    Abstract: An acid-labile protein is described that, when incubated with the 53-Kd acid-stable protein occupied by IGF, converts it to a high molecular weight complex, corresponding to the in vivo form of IGF. This protein is called the acid-labile subunit (ALS) of IGF binding protein complex and is provided in biologically pure form. ALS is useful in treating wounds and promoting cellular growth. The nucleic acid encoding ALS, antibodies binding thereto, and fragments thereof are also disclosed.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: August 10, 1999
    Assignee: Central Sydney Area Health Service
    Inventor: Robert Charles Baxter
  • Patent number: 5932699
    Abstract: Disclosed is a method for determining whether a test protein is capable of interacting with a retinoid X receptor protein. The method involves: (a) providing a host cell which contains (i) a reporter gene operably linked to a protein binding site; (ii) a first fusion gene which expresses a first fusion protein, the first fusion protein including a retinoid X receptor protein covalently bonded to a binding moiety which is capable of specifically binding to the protein binding site; and (iii) a second fusion gene which expresses a second fusion protein, the second fusion protein including the test protein covalently bonded to a gene activating moiety; and (b) determining whether the test protein increases expression of the reporter gene as an indication of its ability to interact with the retinoid X receptor protein. Also disclosed is purified DNA encoding retinoid X receptor-interacting proteins and the polypeptides expressed from such DNA.
    Type: Grant
    Filed: January 13, 1995
    Date of Patent: August 3, 1999
    Assignee: The General Hospital Corporation
    Inventors: David Moore, Wongi Seol, Hueng-Sik Choi
  • Patent number: 5932448
    Abstract: Methods for producing and using bispecific antibodies formed by leucine zippers are provided. Leucine zippers capable of preferentially forming heterodimers are respectively linked to epitope binding components comprising different binding specificities. Bispecific antibodies are formed by pairwise association of the leucine zippers, forming a heterodimer which links the two distinct epitope binding components. Heterodimerization can occur by interaction of the two leucine zipper regions, forming a bispecific antibody. Such a bispecific antibody may be further stabilized by the formation of intermolecular chemical bonds, such as disulfide bonds, between the two monomeric subunits. Subsequent to the formation of such intermolecular bonds between the monomeric subunits, the leucine zippers may be removed or retained. Bispecific antibodies produced by these methods are substantially pure and may be produced in high yields and on a large scale.
    Type: Grant
    Filed: November 29, 1991
    Date of Patent: August 3, 1999
    Assignee: Protein Design Labs., Inc.
    Inventors: J. Yun Tso, Sheri A. Kostelny, Michael S. Cole
  • Patent number: 5928884
    Abstract: The present invention relates to nucleotide sequences of FHIT genes and amino acid sequences of their encoded proteins, as well as derivatives and analogs thereof, and antibodies thereto. The FHIT gene sequence is mutated in diseases involving cell overproliferation, particularly malignancies of the digestive tract. The present invention further relates to the use of FHIT genes and their encoded proteins as diagnostic and therapeutic reagents for the detection and treatment of disease states associated with cell overproliferation.
    Type: Grant
    Filed: February 9, 1996
    Date of Patent: July 27, 1999
    Inventors: Carlo M. Croce, Frances Kay Huebner
  • Patent number: 5925548
    Abstract: Engineered cell surface receptors are described that are constitutively active in the absence of the cytokine, hormone or molecule that normally activates the receptor. Receptors that constitutively signal are generally created by engineering the receptor to form multimers at the cell surface. Disclosed are various DNA, protein and cellular compositions and methods of making and using such constitutively active receptors. Particular examples are fusion proteins in which the stem, transmembrane domain and cytoplasmic domain are derived from a TNF receptor, and the extracellular, multimerizing domain is derived from an erythropoietin receptor. Transfection of such fusion protein constructs into cells is shown to result in a strong cytotoxic effect.
    Type: Grant
    Filed: December 9, 1996
    Date of Patent: July 20, 1999
    Assignee: Board of Regents, The University of Texas System
    Inventors: Bruce A. Beutler, Flavia M. Bazzoni
  • Patent number: 5925543
    Abstract: The invention provides a human NADH dehydrogenase B17 subunit (NDB17) and polynucleotides which identify and encode NDB17. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of NDB17.
    Type: Grant
    Filed: September 12, 1997
    Date of Patent: July 20, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Y. Tom Tang, Neil C. Corley
  • Patent number: 5919638
    Abstract: A set of contiguous and partially overlapping oligonucleotide sequences transcribed from a prostate. Also provided are human disease-specific polypeptides translated from said oligonucleotide sequences and a procedure for producing such polypeptide by recombinant techniques. Antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat prostate diseases, tumors or metastastases are disclosed. Also disclosed is the use of said antibodies, agonists and inhibitors as well as the nucleic acid sequences to screen for, diagnose, prognose, stage and monitor conditions and diseases attributable to prostate tumor, especially prostate cancer. The use of said partial sequence to provide antibodies, agonists and inhibitors as well as partial nucleic acid sequences to screen for, diagnose, stage and monitor diseases and associated with prostate tumor.
    Type: Grant
    Filed: October 8, 1996
    Date of Patent: July 6, 1999
    Assignee: Abbott Laboratories
    Inventors: John C. Russell, Maurice Cohen, Paula N. Friedman, Michael R. Klass, Lisa Roberts-Rapp
  • Patent number: 5919636
    Abstract: Attachment enhanced human embryonic kidney cells, 293, are provided. These cells have been modified to contain a selected mammalian scavenger gene, which has been found to improve the ability of these cells to attach in culture. The improved cells of the invention are useful in assays in which the unmodified 293 cells could be used.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: July 6, 1999
    Assignee: SmithKline Beecham Corporation
    Inventors: Paul George Lysko, Nabil Abd Elsalam Elshourbagy, Mary Ellen Brawner
  • Patent number: 5917022
    Abstract: A process for the removal of endotoxin from a biological product such as proteins for therapeutic use, blood plasma fractions, and albumin solutions that contains endotoxins, which comprises contacting said biological product with a cross-linked hydrophilic matrix comprising a copolymer of allyl dextran and N,N'-methylene bisacrylamide under conditions effective to bind endotoxins in said biological product to said matrix, wherein the total amount of endotoxin in said biological product does not exceed the absorptive capacity of said cross-linked hydrophilic matrix, and recovering purified biological product from which endotoxin has been removed as a result of said binding.
    Type: Grant
    Filed: October 13, 1995
    Date of Patent: June 29, 1999
    Assignee: CSL Limited
    Inventor: Jeffrey Raymond Davies
  • Patent number: 5916758
    Abstract: Isolated nucleic acid encoding human smooth muscle cell-derived migration factor, protein obtainable from the nucleic acid, recombinant host cells transformed with the nucleic acid and use of the protein and nucleic acid sequence are disclosed.
    Type: Grant
    Filed: April 23, 1997
    Date of Patent: June 29, 1999
    Inventors: Mark Robert Hurle, Peter Colon McDonnell, Dean Edward McNulty, Craig Alan Rosen, Ivo Rogulia Siemens, Peter Ronald Young, Tian-Li Yue
  • Patent number: 5915230
    Abstract: The invention provides a method for significantly speeding up the molecular dynamics simulation of large heterogeneous molecular assemblies in which there are a very large number of charged groups and in which there are strong and weak bonds. This method makes practicable the simulation of large protein solutions and thus can be used to simulate protein folding and the binding of substrates to protein molecules among other applications.
    Type: Grant
    Filed: November 21, 1996
    Date of Patent: June 22, 1999
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Bruce J. Berne, Ruhong Zhou